title: Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Michot
authors.affiliation: Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Renaud
authors.initials: R
authors.lastname: Mazeron
authors.affiliation: Department of Nuclear Medicine, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Dercle
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Samy
authors.initials: S
authors.lastname: Ammari
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Charles
authors.initials: C
authors.lastname: Canova
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Aurelien
authors.initials: A
authors.lastname: Marabelle
authors.affiliation: Merck and Co., Inc., Rahway, NJ, USA.
authors.forename: Shelonitda
authors.initials: S
authors.lastname: Rose
authors.affiliation: Merck and Co., Inc., North Wales, PA, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Rubin
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Deutsch
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Ribrag
authors.affiliation: Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. Electronic address: Antonin.LEVY@gustaveroussy.fr.
authors.forename: Antonin
authors.initials: A
authors.lastname: Levy
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011034:Podophyllotoxin / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012074:Remission Induction / Q000379:methods*; D016879:Salvage Therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D003561:Cytarabine; C582435:pembrolizumab; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine
keywords: Abscopal effect; Hodgkin disease; Irradiation; Out-of-field; PD-1; Pembrolizumab